JP2010501594A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501594A5
JP2010501594A5 JP2009525853A JP2009525853A JP2010501594A5 JP 2010501594 A5 JP2010501594 A5 JP 2010501594A5 JP 2009525853 A JP2009525853 A JP 2009525853A JP 2009525853 A JP2009525853 A JP 2009525853A JP 2010501594 A5 JP2010501594 A5 JP 2010501594A5
Authority
JP
Japan
Prior art keywords
variable region
glycoprotein
hcv
modified
linker sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009525853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501594A6 (ja
JP5674310B2 (ja
JP2010501594A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2007/001221 external-priority patent/WO2008022401A1/en
Publication of JP2010501594A publication Critical patent/JP2010501594A/ja
Publication of JP2010501594A6 publication Critical patent/JP2010501594A6/ja
Publication of JP2010501594A5 publication Critical patent/JP2010501594A5/ja
Application granted granted Critical
Publication of JP5674310B2 publication Critical patent/JP5674310B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009525853A 2006-08-25 2007-08-24 組換えｈｃｖ ｅ２糖タンパク質 Expired - Fee Related JP5674310B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2006904635A AU2006904635A0 (en) 2006-08-25 Recombinant E2 Envelope Glycoprotein for Improved Treatment of HCV virus
AU2006904635 2006-08-25
AU2006906090A AU2006906090A0 (en) 2006-11-01 Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment
AU2006906090 2006-11-01
AU2006906282 2006-11-10
AU2006906282A AU2006906282A0 (en) 2006-11-10 Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment
PCT/AU2007/001221 WO2008022401A1 (en) 2006-08-25 2007-08-24 Recombinant hcv e2 glycoprotein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014185095A Division JP5999524B2 (ja) 2006-08-25 2014-09-11 組換えｈｃｖｅ２糖タンパク質

Publications (4)

Publication Number Publication Date
JP2010501594A JP2010501594A (ja) 2010-01-21
JP2010501594A6 JP2010501594A6 (ja) 2010-04-15
JP2010501594A5 true JP2010501594A5 (https=) 2010-10-07
JP5674310B2 JP5674310B2 (ja) 2015-02-25

Family

ID=39106399

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009525853A Expired - Fee Related JP5674310B2 (ja) 2006-08-25 2007-08-24 組換えｈｃｖ ｅ２糖タンパク質
JP2014185095A Expired - Fee Related JP5999524B2 (ja) 2006-08-25 2014-09-11 組換えｈｃｖｅ２糖タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014185095A Expired - Fee Related JP5999524B2 (ja) 2006-08-25 2014-09-11 組換えｈｃｖｅ２糖タンパク質

Country Status (8)

Country Link
US (2) US8535686B2 (https=)
EP (1) EP2061805B1 (https=)
JP (2) JP5674310B2 (https=)
KR (1) KR101500017B1 (https=)
CN (1) CN101563362B (https=)
AU (1) AU2007288129B2 (https=)
CA (1) CA2661814A1 (https=)
WO (1) WO2008022401A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061805B1 (en) * 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Recombinant hcv e2 glycoprotein
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
WO2009146902A1 (en) * 2008-06-03 2009-12-10 Okairòs Ag A vaccine for the prevention and therapy of hcv infections
CA2658714A1 (en) * 2009-03-17 2010-09-17 Thomas Krey Hcv-derived polypeptides and uses thereof
CN102199613A (zh) * 2010-03-25 2011-09-28 国立大学法人东京大学 感染性丙型肝炎病毒高生产hcv突变体及其应用
CN103354748B (zh) 2010-08-04 2016-09-28 麦克法兰博尼特医学健康研究公司 修饰的丙型肝炎病毒蛋白
CN104324373B (zh) * 2010-11-26 2018-10-09 麦克法兰博尼特医学健康研究公司 组合物及其制备方法
WO2013033319A2 (en) * 2011-08-30 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University A cluster of neutralizing antibodies to hepatitis c virus
CN103102394B (zh) * 2013-02-27 2014-06-25 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi49及其应用
CN110049993A (zh) * 2016-09-29 2019-07-23 麦克法兰布奈特医疗研究与公共健康研究所有限公司 组装的糖蛋白
US11008368B2 (en) * 2019-07-26 2021-05-18 The Scripps Research Institute Engineered HCV E2 immunogens and related vaccine compositions
US20230181726A1 (en) * 2020-05-11 2023-06-15 Macfarlane Burnet Institute For Medical Research And Public Health Limited A hepatitis c nucleic acid vaccine comprising a variable domain deleted e2 polypeptide
CN112730851B (zh) * 2021-03-31 2021-06-22 南京立顶医疗科技有限公司 一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10507643A (ja) * 1994-10-21 1998-07-28 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃ型肝炎ウイルス遺伝子型の新規配列、ならびにそれらの予防薬、治療薬および診断薬としての使用
AU1462300A (en) * 1998-11-05 2000-05-22 Board Of Trustees Of The Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
AU7602800A (en) 1999-09-23 2001-04-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
AU2001292667A1 (en) * 2000-09-13 2002-03-26 Hawaii Biotechnology Group, Inc. Immunogenic composition of hepatitis c and methods of use thereof
CN1636050A (zh) * 2001-04-24 2005-07-06 基因创新有限公司 核心糖基化hcv包膜蛋白
IL145440A0 (en) 2001-09-13 2002-06-30 Xtl Biopharmaceuticals Ltd Synthetic hcv envelope proteins and their use for vaccination
CA2552949C (en) * 2004-01-07 2012-10-02 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype
EP2061805B1 (en) * 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Recombinant hcv e2 glycoprotein

Similar Documents

Publication Publication Date Title
JP2010501594A5 (https=)
US6951646B1 (en) Anti hepatitis C virus antibody and uses thereof
Keck et al. Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice
ES2926511T3 (es) Anticuerpos anti-CLEVER-1 humanizados y utilización de los mismos
JP2021508449A5 (https=)
JP2012504602A5 (https=)
JP2009537143A5 (https=)
Lazo et al. A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus
PT1835937E (pt) Composições e métodos para tratar infeção viral
JP2012531219A5 (https=)
EA201170353A1 (ru) Антитела против гепатита с и их применение
JP2018512124A5 (https=)
JP2005528914A5 (https=)
JP5897024B2 (ja) 組成物および方法
Arribillaga et al. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus
JP2018537117A5 (https=)
JP2008532559A5 (https=)
JP2006504645A5 (https=)
US20080248042A1 (en) Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
CN105254756B (zh) 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
El-Awady et al. Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats
TWI432211B (zh) 與登革病毒相關之胜肽及抗體以及其用途
Karsten et al. A novel series of anti-human glycophorin A (CD235a) antibodies defining five extra-and intracellular epitopes
EP2705369B1 (fr) Procédé pour la détection d'une infection par le virus de la dengue
Takao et al. Antibody reactive to a hepatitis C virus (HCV)‐derived peptide capable of inducing HLA‐A2 restricted cytotoxic T lymphocytes is detectable in a majority of HCV‐infected individuals without HLA‐A2 restriction